Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)

INTRODUCTION: Despite the development of new therapies for advanced prostate cancer, it remains the most common cause of cancer and the second leading cause of cancer death in men. It is critical to develop novel agents for the treatment of prostate cancer, particularly those that target aspects of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Scheinberg, Tahlia, Kench, James, Stockler, Martin, Mahon, Kate L, Sebastian, Lucille, Stricker, Phillip, Joshua, Anthony M, Woo, H, Thanigasalam, Ruban, Ahmadi, Nariman, Centenera, Margaret M, Butler, Lisa M, Horvath, Lisa G
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7045211/
https://ncbi.nlm.nih.gov/pubmed/31988233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-033667
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados